Methods for non-surgical treatment of carpal tunnel syndrome
View Patent ↗Provided is a non-surgical method of treatment of carpal tunnel syndrome by administering an effective amount of purified collagenase I and II by injection onto a transverse carpal ligament, without penetrating the transverse carpal ligament. The purified collagenase I and II are obtained from Clostridium histolyticum , and the effective amount is a dose comprising a concentration of approximately 0.29 mg of the purified collagenase I and II to one ml diluent.
1. A non-surgical method of treating carpal tunnel syndrome in a subject in need thereof, the method comprising:
administering by injection, an effective amount of purified collagenase onto a transverse carpal ligament of the subject, wherein the effective amount of the purified collagenase is at least 0.58 mg/ml with a specific activity of at least 1500 SRC units, wherein the purified collagenase is obtained from Clostridium histolyticum and comprises collagenase I and II, and wherein the collagenase is administered with a blunt needle.
2. The method of claim 1 , wherein the collagenase is injected in a liquid pharmaceutically acceptable carrier.
3. The method of claim 1 , wherein the effective amount of the purified collagenase is injected between three and six sites onto a palmar side of the transverse carpal ligament of the subject.
4. The method of claim 1 , wherein the injection is onto the transverse carpal ligament, without penetrating the transverse carpal ligament.
5. The method of claim 1 , wherein the injection is performed with ultrasound guidance to avoid penetration of the transverse carpal ligament.
6. The method of claim 1 , wherein the purified collagenase functions to rupture the transverse carpal ligament.
7. The method of claim 1 , wherein an anesthetic is injected prior to administration of the collagenase, and wherein the injection of the anesthetic makes a needle track.
8. The method of claim 7 , wherein the collagenase is administered following the needle track.
9. The method of claim 2 , wherein the concentration of the purified collagenase in the pharmaceutically acceptable liquid carrier is between 0.58 mg/ml and 1.16 mg/ml.
10. The method of claim 2 , wherein the volume of the pharmaceutically acceptable liquid carrier is between 0.1 ml and 2.0 ml.
11. The method of claim 2 , wherein the liquid pharmaceutically acceptable carrier is selected from the group consisting of normal saline, aqueous NaCl/CaCl 2 buffer, aqueous dextran solution, and aqueous hetastarch solution.